BioSpace News Archive

ANGLE plcANGLE plcANGLE plcANGLE plc, a world leading liquid biopsy company, announces its unaudited interim financial results for the six months ended 30 June 2020.

Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended September 30, 2020 and provided an update of key milestones.

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to the FDA for the purpose of gaining detachable extremity coil magnet

Highlights Announced agreement to acquire Synteract, a mid-sized, full-service CRO focused on the fast growing emerging biopharma sector. GAAP revenue of $1,099.0 million for the three months ended September 30, 2020, representing a sequential increase of 8.4% compared to the three months ended June 30, 2020. Net new business awards of $1,206.3 million and $5,892.1 million for the three and twelve months ended September 30, 2020, representing book-to-bill ratios of 1.10x and 1.31x, respect

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomes Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, to its Scientific Advisory Board.

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020, before the opening of the U.S. financial markets. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as

FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020.